MK-5348-018, NCT00617123: Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) |
|
|
| Completed | 3 | 258 | NA | Vorapaxar 2.5 mg, Placebo | Merck Sharp & Dohme LLC, The TIMI (Thrombolysis in Myocardial Infarction) Study Group, Duke Clinical Research Institute | Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident | 10/10 | 10/10 | | |
TRACER, NCT00527943 / 2006-002809-31: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) |
|
|
| Terminated | 3 | 12944 | NA | Vorapaxar, SCH 530348, MK-5348, Placebo | Merck Sharp & Dohme LLC, Duke Clinical Research Institute | Atherosclerosis, Myocardial Ischemia, Myocardial Infarction | 07/11 | 07/11 | | |
| Completed | 3 | 26449 | NA | Vorapaxar, Placebo | Merck Sharp & Dohme LLC, The Thrombolysis in Myocardial Infarction Study (TIMI) Group | Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident, Peripheral Arterial Disease | 12/11 | 12/11 | | |